Literature DB >> 25492409

Formulation and stability of cytokine therapeutics.

Tiina Lipiäinen1, Marikki Peltoniemi, Sanjay Sarkhel, Teijo Yrjönen, Heikki Vuorela, Arto Urtti, Anne Juppo.   

Abstract

Cytokines are messenger proteins that regulate the proliferation and differentiation of cells and control immune responses. Interferons, interleukins, and growth factors have applications in cancer, autoimmune, and viral disease treatment. The cytokines are susceptible to chemical and physical instability. This article reviews the structure and stability issues of clinically used cytokines, as well as formulation strategies for improved stability. Some general aspects for identifying most probable stability concerns, selecting excipients, and developing stable cytokine formulations are presented. The vast group of cytokines offers possibilities for new biopharmaceuticals. The formulation approaches of the current cytokine products could facilitate development of new biopharmaceuticals.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  biopharmaceuticals characterization; biosimilar; excipients; injectables; lyophilization; oxidation; protein aggregation; protein formulation; protein structure; solid state

Mesh:

Substances:

Year:  2014        PMID: 25492409     DOI: 10.1002/jps.24243

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  17 in total

Review 1.  Factors affecting the physical stability (aggregation) of peptide therapeutics.

Authors:  Karolina L Zapadka; Frederik J Becher; A L Gomes Dos Santos; Sophie E Jackson
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

2.  Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.

Authors:  A Dicitore; E S Grassi; M O Borghi; G Gelmini; M C Cantone; G Gaudenzi; L Persani; M Caraglia; G Vitale
Journal:  J Endocrinol Invest       Date:  2017-03-01       Impact factor: 4.256

3.  Stabilized Interleukin-4-Loaded Poly(lactic-co-glycolic) Acid Films Shift Proinflammatory Macrophages toward a Regenerative Phenotype in Vitro.

Authors:  Alexis M Ziemba; Anthony R D'Amato; Taylor M MacEwen; Devan L Puhl; Abigail N Koppes; Ryan A Koppes; Michelle R Lennartz; Ryan J Gilbert
Journal:  ACS Appl Bio Mater       Date:  2019-02-25

4.  Surface cysteine to serine substitutions in IL-18 reduce aggregation and enhance activity.

Authors:  Jirakrit Saetang; Niran Roongsawang; Surasak Sangkhathat; Supayang Piyawan Voravuthikunchai; Natnaree Sangkaew; Napat Prompat; Teerapol Srichana; Varomyalin Tipmanee
Journal:  PeerJ       Date:  2022-07-05       Impact factor: 3.061

5.  Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation.

Authors:  Najmeh Mahjoubi; Mohammad Reza Fazeli; Rassoul Dinarvand; Mohammad Reza Khoshayand; Ahmad Fazeli; Mohammad Taghavian; Hossein Rastegar
Journal:  Adv Pharm Bull       Date:  2015-11-30

6.  Novel applications for a noninvasive sampling method of the nasal mucosa.

Authors:  Meghan E Rebuli; Adam M Speen; Phillip W Clapp; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-12-23       Impact factor: 6.011

7.  Directed evolution of super-secreted variants from phage-displayed human Interleukin-2.

Authors:  Gertrudis Rojas; Tania Carmenate; Julio Felipe Santo-Tomás; Pedro A Valiente; Marlies Becker; Annia Pérez-Riverón; Yaima Tundidor; Yaquelín Ortiz; Jorge Fernandez de Cossio-Diaz; Luis Graça; Stefan Dübel; Kalet León
Journal:  Sci Rep       Date:  2019-01-28       Impact factor: 4.379

Review 8.  Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.

Authors:  Seungho Lim; Jooho Park; Man Kyu Shim; Wooram Um; Hong Yeol Yoon; Ju Hee Ryu; Dong-Kwon Lim; Kwangmeyung Kim
Journal:  Theranostics       Date:  2019-10-16       Impact factor: 11.556

9.  Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.

Authors:  Deborah Charych; Samira Khalili; Vidula Dixit; Peter Kirk; Thomas Chang; John Langowski; Werner Rubas; Stephen K Doberstein; Michael Eldon; Ute Hoch; Jonathan Zalevsky
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

10.  Automated preparation of clinical grade [68Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platform.

Authors:  Mohammad B Haskali; Peter D Roselt; David Binns; Amit Hetsron; Stan Poniger; Craig A Hutton; Rodney J Hicks
Journal:  EJNMMI Radiopharm Chem       Date:  2019-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.